ADMINISTER OYJ |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.52 EUR | -6.67% |
|
+0.80% | +4.56% |
| 04-22 | BioXcel Therapeutics to Launch At-Home Trial of Potential Bipolar, Schizophrenia Agitation Treatment | MT |
| 04-11 | Gerresheimer shares down on outlook, but key contracts confirmed | RE |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 59.62 | 37.76 | 34.52 | 36.16 | - | - |
| Enterprise Value (EV) 1 | 59.62 | 49.66 | 46.01 | 45.96 | 42.86 | 38.16 |
| P/E ratio | -24.7 x | -53.2 x | -8.93 x | -26.5 x | 63 x | 15.8 x |
| Yield | - | - | - | 2.38% | 3.37% | 4.76% |
| Capitalization / Revenue | - | 0.72 x | 0.45 x | 0.47 x | 0.45 x | 0.43 x |
| EV / Revenue | - | 0.94 x | 0.61 x | 0.6 x | 0.53 x | 0.45 x |
| EV / EBITDA | - | 13.2 x | 16.2 x | 7.35 x | 5.6 x | 4.22 x |
| EV / FCF | - | -2.43 x | 36 x | 20 x | 10.1 x | 7.13 x |
| FCF Yield | - | -41.2% | 2.78% | 5% | 9.92% | 14% |
| Price to Book | - | 1.19 x | 1.26 x | 1.38 x | 1.44 x | 1.49 x |
| Nbr of stocks (in thousands) | 14,194 | 14,194 | 14,325 | 14,350 | - | - |
| Reference price 2 | 4.200 | 2.660 | 2.410 | 2.520 | 2.520 | 2.520 |
| Announcement Date | 25/04/22 | 30/03/23 | 20/03/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | 52.78 | 75.89 | 77.05 | 80.35 | 85 |
| EBITDA 1 | - | 3.765 | 2.849 | 6.25 | 7.65 | 9.05 |
| EBIT 1 | - | 0.126 | -2.954 | 0.3 | 1.5 | 3.5 |
| Operating Margin | - | 0.24% | -3.89% | 0.39% | 1.87% | 4.12% |
| Earnings before Tax (EBT) 1 | - | -0.279 | -3.939 | -0.85 | 1.2 | 3 |
| Net income 1 | -1.792 | -0.703 | -3.886 | -1.3 | 0.6 | 2.2 |
| Net margin | - | -1.33% | -5.12% | -1.69% | 0.75% | 2.59% |
| EPS 2 | -0.1700 | -0.0500 | -0.2700 | -0.0950 | 0.0400 | 0.1600 |
| Free Cash Flow 1 | - | -20.48 | 1.277 | 2.3 | 4.25 | 5.35 |
| FCF margin | - | -38.79% | 1.68% | 2.99% | 5.29% | 6.29% |
| FCF Conversion (EBITDA) | - | - | 44.83% | 36.8% | 55.56% | 59.12% |
| FCF Conversion (Net income) | - | - | - | - | 708.33% | 243.18% |
| Dividend per Share 2 | - | - | - | 0.0600 | 0.0850 | 0.1200 |
| Announcement Date | 25/04/22 | 30/03/23 | 20/03/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 S2 | 2023 S1 | 2023 S2 | 2024 Q2 | 2024 S1 | 2024 Q3 | 2024 Q4 | 2024 S2 | 2025 S1 | 2025 S2 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 28.86 | 39.24 | 36.64 | 19.7 | 39 | 18.1 | 20 | 38.3 | 40.5 | 39.7 |
| EBITDA 1 | 2.748 | 1.556 | 1.293 | 1.7 | 3.5 | 1.3 | 1.5 | 2.7 | 3.9 | 4.3 |
| EBIT 1 | 0.621 | -1.277 | -1.677 | 0.1 | 0.6 | -0.3 | - | -0.2 | 0.9 | 1.2 |
| Operating Margin | 2.15% | -3.25% | -4.58% | 0.51% | 1.54% | -1.66% | - | -0.52% | 2.22% | 3.02% |
| Earnings before Tax (EBT) 1 | 0.264 | -1.589 | -2.35 | -0.1 | 0.3 | -0.5 | -0.3 | -0.9 | 0.6 | 0.6 |
| Net income 1 | -0.134 | -1.821 | -2.065 | -0.3 | - | -0.7 | -0.4 | -1.1 | 0.1 | - |
| Net margin | -0.46% | -4.64% | -5.64% | -1.52% | - | -3.87% | -2% | -2.87% | 0.25% | - |
| EPS 2 | -0.0100 | -0.1300 | -0.1400 | -0.0200 | - | -0.0500 | -0.0300 | -0.0800 | 0.0100 | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 30/03/23 | 31/08/23 | 20/03/24 | - | - | - | - | - | - | - |
1EUR in Million2EUR
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | 11.9 | 11.5 | 9.8 | 6.7 | 2 |
| Net Cash position 1 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | 3.162 x | 4.033 x | 1.568 x | 0.8758 x | 0.221 x |
| Free Cash Flow 1 | - | -20.5 | 1.28 | 2.3 | 4.25 | 5.35 |
| ROE (net income / shareholders' equity) | - | -2.18% | -14.1% | -4.95% | -1.25% | 3.8% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - |
| Book Value Per Share 2 | - | 2.240 | 1.920 | 1.830 | 1.750 | 1.690 |
| Cash Flow per Share 2 | - | 0.1600 | 0.3800 | 0.3100 | 0.4500 | 0.5300 |
| Capex 1 | - | 22.8 | 4.14 | 2.2 | 2.2 | 2.2 |
| Capex / Sales | - | 43.25% | 5.46% | 2.86% | 2.74% | 2.59% |
| Announcement Date | 25/04/22 | 30/03/23 | 20/03/24 | - | - | - |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
2.52
EUR
Average target price
2.9
EUR
Spread / Average Target
+15.08%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +4.56% | 38.95M | |
| +10.67% | 7.47B | |
| -11.79% | 292M | |
| -.--% | 62.2M | |
| -19.85% | 59.83M |
- Stock Market
- Equities
- ADMIN Stock
- Financials Administer Oyj
